Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mesoblast Ltd (MSB.AX)

Mesoblast Ltd (MSB.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Mesoblast Ltd 55 Collins Street Level 38 Melbourne VIC 3000 AUS

https://www.mesoblast.com P: +61 396396036 F: +61 396396030

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Key Statistics

Overview:

Market Capitalization, $K 3,032,134
Shares Outstanding, K 1,290,270
% of Institutional Shareholders 14.15%

Financials:

Annual Sales, $ 17,198 K
Annual Net Income, $ -102,142 K
Last Quarter Sales, $ 2,139 K
Last Quarter Net Income, $ -21,919 K

Growth:

1-Year Return -8.94%
3-Year Return 164.48%
5-Year Return 4.31%
5-Year Revenue Growth -11.46%

Per-Share Information:

Most Recent Earnings 8.18 on 09/06/19
Next Earnings Date N/A
EPS Growth vs. Prev Year -4.00%
Dividend Payout Ratio 0.00%

MSB.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -18.95%
Return-on-Assets % -14.05%
Profit Margin % -593.92%
Debt/Equity 0.12
Price/Sales N/A
Price/Book 3.58
Book Value/Share 0.66
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar